Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS

PURPOSE: In the Phase III, 24-week KRONOS study (NCT02497001), triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) reduced exacerbation rates versus glycopyrrolate/formoterol fumarate (GFF) MDI in patients with moderate-to-very severe chronic obstructive...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Fernando J, Ferguson, Gary T, Bourne, Eric, Ballal, Shaila, Darken, Patrick, Aurivillius, Magnus, Dorinsky, Paul, Reisner, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851632/
https://www.ncbi.nlm.nih.gov/pubmed/33542624
http://dx.doi.org/10.2147/COPD.S286087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851632/
https://www.ncbi.nlm.nih.gov/pubmed/33542624
http://dx.doi.org/10.2147/COPD.S286087

Ejemplares similares